Persistence With Overactive Bladder Pharmacotherapy in a Medicaid Population
Medical Costs After Initiation of Drug Treatment for Overactive Bladder: Effects of Selection Bias on Cost Estimates
Economic Impact of Extended-release Tolterodine versus Immediate-and Extended-release Oxybutynin Among Commercially Insured Persons With Overactive Bladder
Urinary Incontinence in the Nursing Home: Resident Characteristics and Prevalence of Drug Treatment
Treatment of Overactive Bladder: A Model Comparing Extended-release Formulations of Tolterodine and Oxybutynin